Barrington Research Downgrades Lifecore Biomedical to Market Perform
Barrington Research analyst Michael Petusky downgrades Lifecore Biomedical (NASDAQ:LFCR) from Outperform to Market Perform.
Share
Why It Matters
A respected stock analyst became less excited about Lifecore Biomedical. This suggests the analyst thinks the company will just keep up with the market, not beat it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.